Melin N, Sánchez-Taltavull D, Fahrner R, Keogh A, Dosch M, Büchi I, Zimmer Y, Medová M, Beldi G, Aebersold DM, Candinas D, Stroka D. Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury. Cell Death Dis. 2021 Apr 6;12(4):366. doi: 10.1038/s41419-021-03654-3. PMID: 33824326; PMCID: PMC8024273.

Bosch-Guiteras N, Uroda T, Guillen-Ramirez HA, Riedo R, Gazdhar A, Esposito R, Pulido-Quetglas C, Zimmer Y, Medová M, Johnson R. Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs. Genome Res. 2021 Mar;31(3):461-471. doi: 10.1101/gr.265736.120. Epub 2021 Feb 11. PMID: 33574136; PMCID: PMC7919447.


Zimmer Y, Reinhardt HC, Medová M. Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology. Front Oncol. 2020 Oct 15;10:611127. doi: 10.3389/fonc.2020.611127. PMID: 33178619; PMCID: PMC7593708.

Dommann N, Sánchez-Taltavull D, Eggs L, Birrer F, Brodie T, Salm L, Baier FA, Medová M, Humbert M, Tschan MP, Beldi G, Candinas D, Stroka D. The LIM Protein Ajuba Augments Tumor Metastasis in Colon Cancer. Cancers (Basel). 2020 Jul 15;12(7):1913. doi: 10.3390/cancers12071913. PMID: 32679899; PMCID: PMC7409172.

Medová M, Medo M, Hovhannisyan L, Muñoz-Maldonado C, Aebersold DM, Zimmer Y. DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions. Pharmacol Ther. 2020 Nov;215:107617. doi: 10.1016/j.pharmthera.2020.107617. Epub 2020 Jun 28. PMID: 32610116.

Bensimon A, Koch JP, Francica P, Roth SM, Riedo R, Glück AA, Orlando E, Blaukat A, Aebersold DM, Zimmer Y, Aebersold R, Medová M. Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics. Mol Oncol. 2020 Jun;14(6):1185-1206. doi: 10.1002/1878-0261.12696. Epub 2020 May 13. PMID: 32336009; PMCID: PMC7266272.

Koch JP, Aebersold DM, Zimmer Y, Medová M. MET targeting: time for a rematch. Oncogene. 2020 Apr;39(14):2845-2862. doi: 10.1038/s41388-020-1193-8. Epub 2020 Feb 7. PMID: 32034310.

Nisa L, Francica P, Giger R, Medo M, Elicin O, Friese-Hamim M, Wilm C, Stroh C, Bojaxhiu B, Quintin A, Caversaccio MD, Dettmer MS, Buchwalder M, Brodie TM, Aebersold DM, Zimmer Y, Carey TE, Medová M. Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther. 2020 Feb;19(2):614-626. doi: 10.1158/1535-7163.MCT-18-1274. Epub 2019 Nov 19. PMID: 31744898.


Medo M, Aebersold DM, Medová M. ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic data. BMC Bioinformatics. 2019 Nov 9;20(1):563. doi: 10.1186/s12859-019-3144-3. PMID: 31706265; PMCID: PMC6842221.

Muñoz-Maldonado C, Zimmer Y, Medová M. A Comparative Analysis of Individual RAS Mutations in Cancer Biology. Front Oncol. 2019 Oct 18;9:1088. doi: 10.3389/fonc.2019.01088. PMID: 31681616; PMCID: PMC6813200.

Gavini J, Dommann N, Jakob MO, Keogh A, Bouchez LC, Karkampouna S, Julio MK, Medova M, Zimmer Y, Schläfli AM, Tschan MP, Candinas D, Stroka D, Banz V. Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell Death Dis. 2019 Oct 3;10(10):749. doi: 10.1038/s41419-019-1989-z. PMID: 31582741; PMCID: PMC6776510.

Poliaková M, Felser A, Pierzchala K, Nuoffer JM, Aebersold DM, Zimmer Y, Zamboni N, Medová M. Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models. FEBS J. 2019 Jul;286(14):2692-2710. doi: 10.1111/febs.14852. Epub 2019 May 11. PMID: 30993872.

Orlando E, Aebersold DM, Medová M, Zimmer Y. Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. Cancer Lett. 2019 Feb 28;443:189-202. doi: 10.1016/j.canlet.2018.12.001. Epub 2018 Dec 11. PMID: 30550851.


Nisa L, Barras D, Medová M, Aebersold DM, Medo M, Poliaková M, Koch J, Bojaxhiu B, Eliçin O, Dettmer MS, Angelino P, Giger R, Borner U, Caversaccio MD, Carey TE, Ho L, McKee TA, Delorenzi M, Zimmer Y. Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease. Mol Cancer Res. 2018 Dec;16(12):1912-1926. doi: 10.1158/1541-7786.MCR-18-0056. Epub 2018 Aug 14. PMID: 30108165.

Glück AA, Orlando E, Leiser D, Poliaková M, Nisa L, Quintin A, Gavini J, Stroka DM, Berezowska S, Bubendorf L, Blaukat A, Aebersold DM, Medová M, Zimmer Y. Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia. Oncogene. 2018 Jul;37(30):4181-4196. doi: 10.1038/s41388-018-0256-6. Epub 2018 May 2. PMID: 29717265.

Brodie TM, Tosevski V, Medová M. OMIP-045: Characterizing human head and neck tumors and cancer cell lines with mass cytometry. Cytometry A. 2018 Apr;93(4):406-410. doi: 10.1002/cyto.a.23336. Epub 2018 Apr 12. PMID: 29648681.

Poliaková M, Aebersold DM, Zimmer Y, Medová M. The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. Mol Cancer. 2018 Feb 19;17(1):27. doi: 10.1186/s12943-018-0798-9. PMID: 29455660; PMCID: PMC5817809.